RayKnowChina Research Map
Shortlist0

Not yet recruitingMultiple myelomaPhase 4

Registered title, quoted from ClinicalTrials.gov

Isa-VRD in TIE HRMM

An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Peking Union Medical College Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking Union Medical College Hospital北京协和医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07334535, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. ECOG score 0-2

    Inclusion criterion 4

  3. Viral infections including HBV, HCV, HIV, etc.;

    Exclusion criterion 2

  4. Pregnant or lactating women.

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07334535, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Newly diagnosed Multiple myeloma ,meeting the IMWG 2025 definition of high-risk MM (any one criterion):

(1) Del(17p) (>20% of plasma cells) and/orTP53 mutation or(2)One of these translocations cooccurring with 1q+ and/or del(1p32) , or t(4;14), or t(14;16), or t(14;20) or (3) Monoallelic del(1p32) along with 1q+ or biallelic del(1p32) or(4) High β2M (>5.5 mg/dL) with normal creatinine (<1.2 mg/dL) or(5)Or presents with any other high-risk feature: meeting diagnostic criteria for primary plasma cell leukemia or presence of extramedullary plasmacytoma at baseline;

  • Age ≥18 years and ≤80 years;
  • Not eligible for autologous hematopoietic stem cell transplantation or has declined transplantation for other reasons.
  • ECOG score 0-2
  • Expected survival time > 3 months
  • Sufficient organ function is defined as follows: absolute neutrophil count ≥ 1.0×10\^9/L, platelet count ≥ 50×10\^9/L (when the proportion of bone marrow plasma cells is <50%), hemoglobin ≥ 7.5 g/dL; total bilirubin ≤ 1.5 times the upper limit of normal, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal; creatinine clearance rate ≥ 30 mL/min; left ventricular ejection fraction ≥ 50%.
  • Fertile female or male subjects must agree to take effective contraceptive measures during the study period and within the specified time after the last administration.
  • Voluntarily participated in this study, signed the informed consent form, had good compliance, and was cooperative during the follow-up.

Exclusion Criteria:

  • Prior systemic anti-myeloma therapy;
  • Viral infections including HBV, HCV, HIV, etc.;
  • Serious cardiovascular and cerebrovascular diseases, such as: within 6 months before screening, myocardial infarction, unstable angina pectoris, severe arrhythmia, New York Heart Function Classification III-IV grade, or left ventricular ejection fraction <50%.
  • Severe neurological or mental disorders that affect the ability to give informed consent or comply with the protocol.
  • Had an allergic reaction to isatuximab, bortezomib, lenalidomide, dexamethasone or any excipients
  • Pregnant or lactating women.
  • Participated in other interventional clinical studies, or had received other anti-tumor treatments within the specified time before the first administration of this study.
  • The researcher believes that there are any other circumstances unsuitable for participating in this study.

Quoted from ClinicalTrials.gov, NCT07334535, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07334535, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07334535